Eric Wittbrodt

5.1k total citations · 2 hit papers
75 papers, 2.8k citations indexed

About

Eric Wittbrodt is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Nephrology. According to data from OpenAlex, Eric Wittbrodt has authored 75 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Cardiology and Cardiovascular Medicine and 13 papers in Nephrology. Recurrent topics in Eric Wittbrodt's work include Diabetes Treatment and Management (23 papers), Chronic Kidney Disease and Diabetes (9 papers) and Diabetes Management and Research (8 papers). Eric Wittbrodt is often cited by papers focused on Diabetes Treatment and Management (23 papers), Chronic Kidney Disease and Diabetes (9 papers) and Diabetes Management and Research (8 papers). Eric Wittbrodt collaborates with scholars based in United States, United Kingdom and Sweden. Eric Wittbrodt's co-authors include Barry D. Fuchs, H. Scott Bjerke, Dorrie K. Fontaine, David Crippen, Paul E. Marik, Ruth M. Kelleher, Michael J. Murray, Stanley A. Nasraway, Donald B. Chalfin and Douglas B. Coursin and has published in prestigious journals such as PLoS ONE, Diabetes Care and Diabetes.

In The Last Decade

Eric Wittbrodt

74 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult

2002 1.3k citations Eric Wittbrodt et al. profile →
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

2019 223 citations Hiddo J.L. Heerspink, Eric Wittbrodt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Wittbrodt United States	19	1.3k	1.0k	690	469	434	75	2.8k
Douglas B. Coursin United States	28	1.7k 1.4×	1.5k 1.4×	533 0.8×	618 1.3×	782 1.8×	90	3.8k
Judith Jacobi United States	26	2.1k 1.7×	1.5k 1.4×	465 0.7×	661 1.4×	355 0.8×	69	4.0k
Glenn M. Eastwood Australia	33	1.4k 1.1×	464 0.4×	202 0.3×	202 0.4×	854 2.0×	223	4.3k
Mayur B. Patel United States	34	1.9k 1.5×	746 0.7×	132 0.2×	566 1.2×	793 1.8×	140	4.0k
Katarzyna Kotfis Poland	26	1.2k 1.0×	542 0.5×	50 0.1×	390 0.8×	414 1.0×	114	2.9k
Andrew D. Bersten Australia	37	1.4k 1.1×	535 0.5×	149 0.2×	158 0.3×	925 2.1×	164	4.9k
Michael J. Jacka Canada	21	986 0.8×	365 0.3×	218 0.3×	106 0.2×	1.4k 3.1×	59	3.0k
Joanna L. Stollings United States	23	1.5k 1.2×	399 0.4×	62 0.1×	169 0.4×	484 1.1×	96	2.9k
Lars W. Andersen Denmark	41	879 0.7×	266 0.3×	146 0.2×	140 0.3×	1.6k 3.6×	168	6.1k
Patrick E. Wright United States	13	1000 0.8×	386 0.4×	87 0.1×	189 0.4×	333 0.8×	19	2.4k

Countries citing papers authored by Eric Wittbrodt

Since Specialization

Citations

This map shows the geographic impact of Eric Wittbrodt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Wittbrodt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Wittbrodt more than expected).

Fields of papers citing papers by Eric Wittbrodt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Wittbrodt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Wittbrodt. The network helps show where Eric Wittbrodt may publish in the future.

Co-authorship network of co-authors of Eric Wittbrodt

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Wittbrodt. A scholar is included among the top collaborators of Eric Wittbrodt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Wittbrodt. Eric Wittbrodt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Delgado, Diego, et al.. (2025). Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review. Orphanet Journal of Rare Diseases. 20(1). 29–29. 4 indexed citations

Heerspink, Hiddo J.L., Stephen Nolan, Juan Jesús Carrero, et al.. (2024). Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort. Advances in Therapy. 41(8). 3264–3277. 5 indexed citations

Pecoits‐Filho, Roberto, Maria Cristina Ribeiro de Castro, Ana Cebrián, et al.. (2023). #3667 REVEAL-CKD: PREVALENCE OF UNDIAGNOSED STAGE 3 CHRONIC KIDNEY DISEASE IN AUSTRALIA, BRAZIL, CANADA AND SPAIN. Nephrology Dialysis Transplantation. 38(Supplement_1). 2 indexed citations

Lamerato, Lois, Glen James, Heleen van Haalen, et al.. (2022). Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study. BMC Nephrology. 23(1). 166–166. 17 indexed citations

Wittbrodt, Eric, Salvatore Barone, Matthew Arnold, et al.. (2021). REVEAL-CKD: Prevalence of Undiagnosed Early CKD in France and Japan. Journal of the American Society of Nephrology. 32(10S). 715–716. 1 indexed citations

Wittbrodt, Eric, et al.. (2021). Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population. Journal of Diabetes and its Complications. 35(4). 107859–107859. 1 indexed citations

Sánchez, Juan José García, Juliette C. Thompson, David A. Scott, et al.. (2021). Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. Advances in Therapy. 39(1). 193–220. 22 indexed citations

Real, Jordi, Bogdan Vlacho, Manel Mata‐Cases, et al.. (2021). Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovascular Diabetology. 20(1). 139–139. 17 indexed citations

Wittbrodt, Eric, Narinder Bhalla, Karolina Andersson Sundell, et al.. (2020). Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry. Endocrinology Diabetes & Metabolism. 3(3). e00133–e00133. 8 indexed citations

10.

James, Glen, Anna Niklasson, Katarina Hedman, et al.. (2020). Characteristics, Symptom Severity, and Experiences of Patients Reporting Chronic Kidney Disease in the PatientsLikeMe Online Health Community: Retrospective and Qualitative Study. Journal of Medical Internet Research. 22(7). e18548–e18548. 12 indexed citations

11.

Wittbrodt, Eric, et al.. (2020). PUK6 COST AND HEALTHCARE RESOURCE USE IN PATIENTS WITH ANEMIA IN CKD USING LINKED US CLAIMS AND ELECTRONIC HEALTH RECORDS. Value in Health. 23. S378–S378. 1 indexed citations

12.

Reed, Shelby D., Helen Dakin, Frauke Becker, et al.. (2019). Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care. 43(2). 374–381. 6 indexed citations

13.

Strange, Charlie, et al.. (2019). <p>Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD</p>. International Journal of COPD. Volume 14. 1377–1388. 5 indexed citations

14.

Lauffenburger, Julie C., Roya Ghazinouri, Saira Jan, et al.. (2019). Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: The ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic randomized trial. PLoS ONE. 14(4). e0214754–e0214754. 34 indexed citations

15.

Wittbrodt, Eric, et al.. (2018). Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β<sub>2</sub>-agonist via dry-powder inhalers and pressurized metered-dose inhalers. International Journal of COPD. Volume 14. 101–114. 4 indexed citations

16.

Fine, Perry G., Yen‐Wen Chen, Eric Wittbrodt, & Catherine Datto. (2018). Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy. Supportive Care in Cancer. 27(2). 687–696. 16 indexed citations

17.

Lauffenburger, Julie C., Jennifer Lewey, Saira Jan, et al.. (2017). Rationale and design of the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic trial. Contemporary Clinical Trials. 59. 57–63. 6 indexed citations

18.

Wittbrodt, Eric, et al.. (2016). Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease. Journal of Managed Care & Specialty Pharmacy. 22(4). 326–336. 7 indexed citations

19.

Wittbrodt, Eric. (2005). Daily Interruption of Continuous Sedation. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 25(5P2). 3S–7S. 17 indexed citations

20.

Mann, Henry J., et al.. (1998). Effect of Pharmacokinetic Sampling Methods on Aminoglycoside Dosing in Critically Ill Surgery Patients. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(2). 371–378. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact